Study Title
PNOC029: Nivolumab and DAY101 for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults
Protocol ID
PNOC029
Disease (Sub Disease)
Craniopharyngioma
Diagnosis Stage
Newly diagnosed
Relapsed/Refractory
Relapsed/Refractory
Sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Collaborators
Bristol-Myers Squibb
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc.
Links
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year to 39 Years
International registry ID's
NCT05465174
| Study Title | PNOC029: Nivolumab and DAY101 for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults |
|---|---|
| Protocol ID | PNOC029 |
| Disease (Sub Disease) | Craniopharyngioma |
| Diagnosis Stage | Newly diagnosed Relapsed/Refractory |
| Sponsor | Australian & New Zealand Children's Haematology/Oncology Group |
| Collaborators | Bristol-Myers Squibb/ Day One Biopharmaceuticals, Inc. |
| Links | https://clinicaltrials.gov/ct2/show/NCT05465174 |
| Trial Status | Preparing to Open |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 1 Year to 39 Years |
| International registry ID's | NCT05465174 |